Melbourne Clinical Trials

Inpatient Only Study

Non-alcoholic fatty liver disease (NAFLD) is the largest chronic liver disease in the world with the prevalence estimated to be approximately 30% of adults in developed countries such as Australia and the United States. There are currently no drugs available for it's treatment.

3 nights
1 follow up call visits

This study is looking at potential new treatment for non-alcoholic fatty liver disease (NAFLD). The purpose of this study is to investigate the safety and tolerability of this new medication in healthy participants and how it is absorbed and processed by the body.

The trial has been approved by an independent ethics committee and you will be reimbursed for your time.


Biological Sex Healthy males or females
Age 18-55 years old
BMI 18 – 32 kg/m2
Medications Not taking any medication (including hormonal contraceptives)
Medical History No significant medical history
Smoking History Non-smokers or social smokers (no more than 5 cigarettes per week)